Comparison of the therapeutic effects of daprodustat and ESA

Daprodustat is a new oral drug that is a hypoxia-inducible factor prolyl hydroxylase inhibitor (HIF-PHI). It treats chronic kidney disease anemia (CKD) by activating endogenous erythropoietin (EPO). Unlike traditional **erythropoietin (ESA)** treatments, ESA supplements EPO through exogenous injection to increase red blood cell production. The main differences between the two are reflected in the mode of administration, treatment mechanism and safety.

1. Therapeutic effect:ESA drugs often need to be administered by injection, and patient compliance is poor, and long-term use may cause cardiovascular problems. In contrast, daprostat is administered orally, avoiding the inconvenience of injection, and can promote erythropoiesis by stimulating the synthesis of endogenous EPO in the body. Clinical studies have shown that daprostat can effectively increase hemoglobin levels, reduce the need for blood transfusions, and improve iron metabolism, providing a more stable effect compared with traditional ESA treatment.

2. Safety:The use of ESA is associated with cardiovascular adverse reactions such as hypertension and thromboembolism, while daprostat has been shown to have better cardiovascular safety in clinical trials, although changes in blood pressure still need to be paid attention to. It is worth noting that daprostat can better control hemoglobin levels and avoid the risk of excessive hemoglobin that may occur during ESA treatment, thus reducing the occurrence of cardiovascular adverse reactions.

3. Patient compliance: Since daprostat is an oral drug, compared with ESA that requires regular injections, patient compliance is significantly improved. In long-term use, dapostat has better patient tolerance and treatment stability than ESA.

Overall, compared with ESA, dapostat has shown better therapeutic effect, stability and safety in the treatment of anemia in chronic kidney disease, especially in terms of patient compliance and cardiovascular safety.

Reference materials:https://en.wikipedia.org/wiki/Daprodustat